Insulin resistance is one of the most significant metabolic conditions in modern populations, underpinning type 2 diabetes, metabolic syndrome, non-alcoholic fatty liver disease, and cardiovascular risk. GLP-1 receptor agonists are among the most studied pharmaceutical interventions for improving insulin sensitivity. Understanding how insulin resistance develops and the mechanisms by which GLP-1R agonism addresses it provides essential context for anyone researching these compounds.